Through Cost Plus Drugs, Cuban is challenging pharmacy middlemen, manufacturing shortages, and opaque pricing — all while bypassing the industry’s biggest players
“It’s Broken”: Why Mark Cuban Is Coming for Healthcare
Mark Cuban, the billionaire entrepreneur and investor, isn’t just criticizing America’s healthcare system — he’s actively disrupting it. On the Equity podcast, Cuban laid bare the core issue: Americans don’t know what their medications cost until they’re handed a bill — and that, he says, is by design.
- Opaqueness is intentional: Pharmacy benefit managers (PBMs) set most prices behind closed doors.
- Consumers left guessing: Patients often don’t know if they can afford their prescriptions until it’s too late.
The Cost Plus Drugs Model: Transparency Over Profits
Launched in 2022, Cost Plus Drugs is Cuban’s direct-to-consumer online pharmacy with a radically simple pricing model:
- Cost + 15% markup + $5 pharmacy fee + shipping
- Now expanding to local pickup options
This transparent formula is in stark contrast to traditional pricing strategies that factor in insurance reimbursements, PBM-negotiated rates, and hidden rebates.
- One example: A generic chemotherapy drug that might cost thousands at a pharmacy costs just $21 on Cost Plus Drugs.
- Message to the industry: “They price to market; we price based off of cost.”
Fixing a Broken Supply Chain: Cuban Builds His Own Factory
Cuban’s disruption doesn’t stop at sales. To fight drug shortages and bypass traditional bottlenecks, he’s built a robotics-driven manufacturing plant in Dallas.
- Rapid manufacturing: New drugs can be produced and shipped in four hours.
- Focus on shortages: Including pediatric cancer meds, Pitocin, and sterile water — all frequently hard to find.
Cuban alleges that some shortages are strategic, designed to allow manufacturers to inflate prices — a practice he’s determined to counter.
A Strategy Built on Defiance
Unlike Amazon or other health tech entrants, Cuban refuses to work with PBMs, even if that means slower growth.
- A clean break: “I just won’t work with them,” he said. “Because that’s not what’s best aligned for patients.”
- Calling out Amazon: Even Amazon Pharmacy is tied to PBMs, making them part of the problem, Cuban argues.
His long game is clear: independence over dependence, even if it means fighting the entrenched $5 trillion system solo.
Razor-Thin Margins — But a Broader Play
Shipping generic drugs to individuals is not a high-margin business, but manufacturing and scale offer sustainability.
- Profitable segments: In-house manufacturing is already proving to be a profitable part of the business.
- Vertical integration: Owning the supply chain offers control, faster reactions, and better margins over time.
Advice to Founders: Don’t Follow the Herd
For entrepreneurs dreaming of healthcare disruption, Cuban offered clear advice: avoid the incumbents, even if they seem like a fast path to revenue.
- “Don’t be dependent on them. All of healthcare is basically arbitrage,” he said.
- Cuban’s strategy: be fast, adaptive, and lean, while legacy players are slow and bogged down by their own infrastructure.
Cuban vs. The System: A Founder’s Edge
Cuban frames the fight as speed vs. size. While massive healthcare firms protect their legacies, startups have agility.
“When you run with the elephants, there’s the quick and the dead,” he said.
“They can’t react as quickly. That’s always going to give the founder an edge.”
This philosophy is what powers Cuban’s challenge to the U.S. healthcare system: don’t play by their rules. Break them.
